Market Analysis:North America Topical Drug Delivery Market
North America Topical Drug Delivery Market is expected to reach USD 89.3 billion by 2024 from USD 48.0 billion in 2016, growing at a CAGR of 8.0% in the forecast period 2017 to 2024. The new market report contains data for historic years 2014 & 2015, the base year of calculation is 2016 and the forecast period is 2017 to 2024.
Market Segmentation: North America Topical Drug Delivery Market
- The North America Topical Drug Delivery Market is segmented on the basis of product type, distribution channel, end user, and geography.
- On the basis of product typethe market is segmented into transdermal drug delivery devices and topical drug delivery formulations. Topical drug delivery formulations are further segmented based on form into solid, semi-solid, and liquid. The semi solid segment is further classified into ointments, creams, lotions, gels, and pastes. The solid drugs segment is further segmented into powders and suppositors. The liquid drugs segment is further classified into solutions and suspensions.
- The transdermal drug delivery devices market segment is further segmented into patches and gels. In 2016, on the basis of product type topical drug delivery formulations segment dominated the market by 72.6% share, however transdermal drug delivery devices market is expected to grow at the highest CAGR of 14.1% in the forecast period 2017 to 2024.
- On the basis of end users, the market is segmented into hospitals, home healthcare, clinics, diagnostic centers, and others.
Company Share Analysis: North America Topical Drug Delivery Market
The North America topical drug delivery market is highly fragmented with various companies operating in local regions. The major players have used various strategies such as new product launches, expansions, agreements, joint ventures, partnerships, acquisitions, and others to increase their footprints in this market.
Major Market Competitors: North America Topical Drug Delivery Market
Some of the major players operating in this market are MedPharm, Janssen Pharmaceuticals, Inc. (Johnson & Johnson Services Inc A J&J Company), Crescita Therapeutics, Galderma S.A., Biofarmitalia s.r.l, Pharmatek Laboratories, Inc., Stiefel Laboratories, Inc., Tapemark, Acrux Limited, Nitto Denko Corporation, Valeant Pharmaceuticals International, Inc., Skinvisible Pharmaceuticals, Inc., Mylan Pharmaceuticals Inc., Hisamitsu Pharmaceutical Co., Inc., Pocono Coated Products LLC, TheraSolve NV., Samyang Biopharmaceuticals Corporation, Lohmann Therapie-Systeme AG, Prosollus Pharmaceuticals, Easton Pharmaceuticals Inc., Novosis AG, Antares Pharma, Inc., Endo Pharmaceuticals Inc., Transdermal Technologies, Inc., Sheffield Pharmaceuticals, Inc., Solvay, and 3M Drug Delivery Systems.